Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discusses challenges and novel approaches for managing patients with cutaneous T-cell lymphoma (CTCL). Dr Osborne emphasizes the importance of collaboration between hematologists and dermatologists to care for this patient group, and further discusses novel targeted agents, including brentuximab vedotin and mogamulizumab, as treatments for CTCL. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.